Pill controversy put to rest

An Australian-led study has given the all-clear to oral contraceptives that contain drospirenone.

This follows concerns that the ingredient places women at increased risk of  venous thromboembolism (VTE).

The study, which compared the drospirenone-containing contraceptives with levonorgestrel and other progestins failed to find a significant difference in VTE